Amneal Pharmaceuticals is adding a biosimilar rival to Xolair (omalizumab) to its biosimilars pipeline, with the Kashiv Biosciences-developed product becoming the eighth biosimilar in the firm’s portfolio.
With three biosimilars already on the market in the US – Alymsys (bevacizumab-maly), Fylnetra (pegfilgrastim-pbbk), and Releuko (filgrastim-ayow) – Amneal also has denosumab rivals to Prolia and Xgeva in its pipeline, courtesy of a recent partnership with mAbxience. (Also see "Amneal And mAbxience Ally On Denosumab In US" - Generics Bulletin, 13 October, 2023.) Meanwhile, the company also has on-body injector and pre-filled autoinjector versions of pegfilgrastim in development
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?